title: Transdermal iontophoresis with verapamil and dexamethasone in the acute phase of peyronie's disease. Our experience.
abstract: OBJECTIVE
  To evaluate the treatment of Peyronie's disease (PD) with verapamil and dexamethasone iontophoresis.
  
  
  METHODS
  Twenty nine patients with PD were treated by means of a Miniphysionize" dispositive 3 sessions a week during 4 consecutive weeks.  5mL of a combination of  verapamil(10mg.) and dexamethasone (4mg.) were transdermally administered with a 2.5 mA current during 20 min. The aim  is to evaluate treatment  efficacy in  correcting penile curvature (Kelami test), plaque size (penis ultrasound (US)) improvement of pain and,  other parameters like erectile function (EF), intercourse capacity or adverse effects of the treatment, which were evaluated with  questionnaires.
  
  
  RESULTS
  All patients completed the treatment protocol (12 sessions) and a total number of 348 sessions of iontophoresis were performed.  After treatment,  3 patients (10.7%) continued with pain, but it disappeared in 25 of them (89.3%). A decrease of the size of the  plaque was observed in 13  patients (44.8%),  even disappearance in 4 patients (13.8%). No patient had curvature decrease after treatment. However, EF (IIEF score)  and ability for intercourse  improved in 3 (10.3%)  and 4 patients (13.8%) respectively.
  
  
  CONCLUSIONS
  Verapamil and dexamethasone iontophoresis is a safe and reliable treatment resolving painful erections in the acute phase of PD. However its efficacy in solving  penile curvature and erectile dysfunction (ED) is more limited.
authors.affiliation: Urology Department and Unidad de Enfermería de Urología, Hospital del Henares, Coslada, Madrid, Spain. pgabad@hotmail.com
authors.forename: Pablo
authors.initials: P
authors.lastname: Garrido Abad
authors.forename: Almudena
authors.initials: A
authors.lastname: Coloma
authors.forename: Luis Miguel
authors.initials: LM
authors.lastname: Herranz
authors.forename: Milagros
authors.initials: M
authors.lastname: Jiménez
authors.forename: Carlos
authors.initials: C
authors.lastname: Suárez
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Prieto
authors.forename: Teresa
authors.initials: T
authors.lastname: Formoso
authors.forename: Manuel
authors.initials: M
authors.lastname: Fernández Arjona
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D003075:Coitus; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007478:Iontophoresis / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010146:Pain; D010410:Penile Erection / Q000502:physiology; D010411:Penile Induration / Q000188:drug therapy* / Q000473:pathology; D010413:Penis / Q000000981:diagnostic imaging / Q000473:pathology; D012189:Retrospective Studies; D014463:Ultrasonography; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D002121:Calcium Channel Blockers; D003907:Dexamethasone; D014700:Verapamil